Isoniazid Injection Rx
Generic Name and Formulations:
Isoniazid 100mg/mL; soln for IM inj; contains chlorobutanol.
Indications for Isoniazid Injection:
Treatment and prophylaxis of susceptible tuberculosis.
Treatment: 5mg/kg up to 300mg daily in a single dose; or 15mg/kg up to 900mg/day, 2 or 3 times/week. See literature for regimens in patients with pulmonary TB without HIV, pulmonary TB with HIV, patients with extra pulmonary TB, pregnant women with TB, and patients with multi-drug resistant TB. Prevention: >30kg: 300mg/day in a single dose. Malnourished, predisposed to neuropathy: give concomitant pyridoxine.
Treatment: 10–15mg/kg up to 300mg daily in a single dose; or 20–40mg/kg up to 900mg/day, two or three times/week. See literature for regimens in patients with pulmonary TB without HIV, pulmonary TB with HIV, patients with extra pulmonary TB, pregnant women with TB, and patients with multi-drug resistant TB. Prevention: 10mg/kg (up to 300mg daily) in a single dose. Malnourished, predisposed to neuropathy: give concomitant pyridoxine.
Drug-induced hepatitis. Previous isoniazid-associated hepatic injury. Severe adverse reactions to isoniazid (eg, drug fever, chills, arthritis). Acute liver disease of any etiology.
Increased risk of severe or fatal hepatitis; monitor, discontinue if signs of hepatic damage detected. Defer in acute hepatic disease. Alcoholics. Chronic liver disease. Perform LFTs prior to therapy, then periodically as needed. Severe renal dysfunction. >35yrs old. Peripheral neuropathy or conditions predisposing to neuropathy. Injection drug use. Women belonging to minority groups, particularly in the post-partum period. HIV seropositive. Perform eye exams if visual symptoms occur. Neonates. Pregnancy (Cat.C). Nursing mothers.
Concomitant hepatotoxic agents: may cause fatal liver dysfunction. Concomitant alcohol may be associated with higher incidence of isoniazid hepatitis. Monitor prothrombin time with concomitant anticoagulants. May potentiate phenytoin, carbamazepine, theophylline, valproate (adjust dose). May antagonize ketoconazole. May inhibit assays for serum folate and Vit. B12 (consider alternative methods).
Peripheral neuropathy (esp. in slow acetylators), elevated serum transaminases (SGOT; SGPT), bilirubinemia, bilirubinuria, jaundice, hepatitis (may be fatal), nausea, vomiting, epigastric distress, pancreatitis, blood dyscrasias, hypersensitivity reactions (eg, skin eruptions, TEN, DRESS), pyridoxine deficiency, hyperglycemia, pellagra, metabolic acidosis, gynecomastia, rheumatic syndrome, SLE-like syndrome, inj site reactions.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users